Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation
 between the intensive care group and the usual care group for patients with hypertension
 accompanied by aortic valve disease and evaluate an influence of blood pressure regulation on
 improvement of left ventricular hypertrophy and its safety
1.Primary objectives

 - To evaluate changes from baseline in LVM at V5 (24M)

 2.Secondary objectives

 1. To evaluate changes from baseline in LV global longitudinal strain at V5 (24M)

 2. To evaluate changes from baseline in E/E' (E: early diastolic LV inflow velocity, E':
 early diastolic mitral annulus velocity) at V5 (24M)

 3. To evaluate changes from baseline in LV volumes, a stroke volume index and LV ejection
 fraction at V5 (24M)

 4. To evaluate a rate of disease progression

 -  In case of Aortic stenosis (AS), to evaluate changes from baseline in Aortic Valve
 Area (AVA), Vmax, Mean Pressure Gradient (PG) and Valvulo-arterial impedance (Zva)
 at V5 (24M)

 -  In case of Aortic regurgitation (AR), to evaluate changes from baseline in Vena
 contracta at V5 (24M)

 5. To evaluate changes from baseline in blood pressure at V2(6M), V3(12M), V4(18M) and
 V5(24M)

 6. To evaluate a cumulative incidence rate for each visit time point

 -  Death, Cardiovascular(CV) death, Heart Failure(HF), Myocardial Infarction(MI),
 Hospitalization, Aortic Valve Replacement(AVR)

 7. To evaluate outcomes of adverse events, physical examination, vital signs (pulse) and
 laboratory tests (hematological examination, blood biochemical examination, urine test
 and pregnancy test)
Inclusion Criteria:

 1. Male or female aged ≥ 19 years and < 80 years

 2. Diagnosis of mild-moderate AS or mild-moderate AR

 3. Applicable to 2.0~3.9 m/s of aortic jet velocity for mild-moderate AS or to 0.2~0.6 cm
 of Vena contracta for mild-moderate AR

 4. Diagnosis of hypertension (SBP > 130 mmHg if being treated or SBP > 140 mmHg if being
 untreated)

 5. For females of childbearing potential; negative pregnancy test results during the
 screening period and prior to administration of the investigational product, and
 agreement on use of medically allowable contraceptive measures (condom, oral
 contraceptive pills, injectable or implantable contraceptives, intrauterine devices,
 birth control patches, etc.) during the study period

 6. Voluntary written consent to taking part in the clinical study and willingness to
 comply with requirements of the study

 Exclusion Criteria:

 1. History of a cardiac valve replacement surgery (replacement surgery of mitral valve,
 aortic valve or tricuspid valve)

 2. Accompanied by severe mitral regurgitation

 3. Admitted to needing a surgery by the current treatment guidelines

 4. Accompanied by symptoms such as angina pectoris, exertional dyspnea, syncope, etc.

 5. < 50% of left ventricular ejection fraction

 6. History of hypersensitivity reaction to active ingredients of the investigational
 product (Amlodipine, Losartan and Chlorthalidone), dihydropyridine derivatives,
 thiazide drugs and other sulfonamide derivatives or their compositions

 7. Pregnant or breastfeeding

 8. Symptomatic orthostatic hypotension

 9. Severe liver failure or renal failure (< 30 mL/min of creatinine clearance)

 10. Hereditary angioedema or history of angioedema at treatment with ACE inhibitors or
 angiotensin II receptor blockers

 11. Primary hyperaldosteronism

 12. Genetic problems such as galactose intolerance, Lapp Lapp lactase deficiency or
 glucose-galactose malabsorption

 13. Anuria

 14. Refractory hypokalemia

 15. Hyponatremia or hypercalcemia

 16. Symptomatic hyperuricemia (history of gout or uric acid lithiasis)

 17. Untreated Addison's disease

 18. Appropriately uncontrolled diabetes

 19. Congenital or incurable hypertension

 20. Diagnosis of severe cerebrovascular disorders (stroke, cerebral infarction, cerebral
 hemorrhage, etc.) within six months prior to the date of ICF obtainment

 21. Wasting disease, autoimmune disease or connective tissue disease

 22. Diagnosis of malignant tumor within five years prior to the date of ICF obtainment

 23. Administration of another investigational product within four weeks prior to the date
 of ICF obtainment

 24. For a patient who is taking anticoagulants and thrombolytic agents; considered
 difficult to keep a stable dosage/regimen by the investigator.

 25. Considered unsuitable to be a subject by the investigator